Drug
Cort118335
Cort118335: highest development phase Phase 1, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CORT118335 Oral NCT03878264 | Phase 1 | Healthy |
Latest
No recent events.
Follow Cort118335 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.